EraGen Announces Strategic Partnership, Licensing Agreement with Illumina.
EraGen Biosciences Inc. and Illumina Inc. announced the formation of a strategic partnership and the execution of non-exclusive licensing agreements. Under these licensing agreements, EraGen Biosciences will have access to Illumina's BeadXpress platform for the continued development and commercialization of molecular-based, high-throughput clinical multiplexed assays with its unique, patented MultiCode(R)-PLx technology. EraGen has proven commercial success with multiplex molecular assays for the infectious disease and genetic disorder markets. Illumina has licensed EraGen's MultiCode-PLx technology for the life sciences, research and clinical markets. This partnership is part of EraGen's strategy to continue to expand its commercial efforts in the molecular diagnostics market.
